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OBJECTIVES This SHOCK Study report seeks to provide an overview of patients with cardiogenic shock
(CS) complicating acute myocardial infarction (MI) and the outcome with various treat-
ments. The outcome of patients undergoing revascularization in the SHOCK Trial Registry
and SHOCK Trial are compared.
BACKGROUND Cardiogenic shock is the leading cause of death in patients hospitalized for acute MI. The
randomized SHOCK Trial reported improved six-month survival with early revasculariza-
tion.
METHODS Patients with CS complicating acute MI who were not enrolled in the concurrent randomized
trial were registered. Patient characteristics were recorded as were procedures and vital status
at hospital discharge.
RESULTS Between April 1993 and August 1997, 1,190 patients with CS were registered and 232 were
randomized in the SHOCK Trial. Predominant left ventricular failure (78.5%) was most
common, with isolated right ventricular shock in 2.8%, severe mitral regurgitation in 6.9%,
ventricular septal rupture in 3.9% and tamponade in 1.4%. In-hospital Registry mortality was
60%, with ventricular septal rupture associated with a significantly higher mortality (87.3%)
than all other categories (p , 0.01). The risk profile and mortality were lower for Registry
patients who were managed with thrombolytic therapy and/or intra-aortic balloon counter-
pulsation, coronary angiography, angioplasty and/or coronary artery bypass surgery. After
adjusting for these differences, the extent to which survival was improved with early
revascularization was similar to that observed in the randomized SHOCK Trial.
CONCLUSIONS In this prospective Registry the etiology of CS was a mechanical complication in 12%. The
similarity of the beneficial treatment effect in patients undergoing early revascularization in
the SHOCK Trial Registry and SHOCK Trial provides strong support for the generaliz-
ability of the SHOCK Trial results. (J Am Coll Cardiol 2000;36:1063–70) © 2000 by the
American College of Cardiology
Over the past 15 years, 30-day mortality and overall
complications of acute myocardial infarction (MI) have
been substantially reduced by the use of reperfusion therapy
(1–3). However, cardiogenic shock (CS) remains the lead-
ing cause of death in patients hospitalized with acute MI
(4). Thrombolytic therapy alone has had a limited effect on
the outcome of patients presenting with pump failure (1,3).
Further insights into the mechanisms of shock and the
outcomes of various treatment modalities currently in use
are needed to substantially alter the high mortality rate of
CS.
Nonrandomized studies have reported a reduced mortal-
ity rate for patients with CS undergoing revascularization
(5–10). A recently reported international randomized trial,
SHould we emergently revascularize Occluded Coronaries
for cardiogenic shocK? (the SHOCK Trial), was supported
by the National Heart, Lung, and Blood Institute. The
SHOCK Trial assessed the effects on 30-day mortality of a
direct invasive strategy (emergency early coronary angiog-
raphy and revascularization), compared with a strategy of
initial medical stabilization (including thrombolysis and
intra-aortic balloon counterpulsion [IABP]) followed by
delayed mechanical revascularization as clinically deter-
mined (11). Concurrent with this randomized trial, data
have also been collected on patients with suspected CS
complicating acute MI who were not randomized at the 36
participating institutions. This Registry of the SHOCK
Trial offers a unique opportunity to: 1) further define the
mechanisms responsible for CS in patients with acute MI,
2) review the utilization rates of therapeutic modalities and
their impact on mortality, and 3) compare the effect of early
revascularization on mortality in both the Registry and Trial
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cohorts. This report provides an overview of the entire
SHOCK study. In-depth analyses of the major etiologies of
shock, and the various treatment modalities, are presented
in other reports in this supplementary issue of the Journal.
Enrollment in the SHOCK Trial Registry and SHOCK
Trial started in April 1993 and was completed for the
Registry on August 31, 1997, and for the Trial on Novem-
ber 30, 1998. Eleven hundred and ninety patients were
enrolled in the SHOCK Trial Registry, and 232 patients
were enrolled in the SHOCK Trial as of August 31, 1997.
This is the largest body of experience prospectively collected
to date relating to unselected patients with CS complicating
acute MI.
METHODS
Patient sample. One thousand one hundred ninety pa-
tients with suspected CS complicating acute MI were
prospectively registered. A local discharge diagnosis of acute
MI and CS (DRG’s 410 and 785.51) or a suspected
diagnosis of CS complicating acute MI, regardless of the
final discharge diagnosis, constituted the criteria for registry
enrollment.
Thirty-six centers were initiated in a staggered fashion,
with the first patient enrolled in April 1993. Seven hundred
and thirty patients (61%) were registered in 24 U.S. centers,
256 (22%) in five Canadian centers, 76 (6%) in four Belgian
centers and 128 (11%) in Australia, New Zealand and
Brazil. All centers obtained Institutional Review Board or
Ethics Committee approval for the abstraction of medical
records.
Enrollment in the SHOCK Trial Registry rather than the
randomized SHOCK Trial occurred if a patient with
suspected CS failed to meet all trial inclusion criteria or
specified time windows, met a trial exclusion criterion, or
was unable or refused to give consent. As previously
reported (12), the criteria for CS for the randomized
SHOCK Trial consisted of: 1) hypotension (systolic blood
pressure ,90 mm Hg for at least 30 min, need for
vasopressors, or IABP support); 2) clinical evidence of end
organ hypoperfusion; and 3) confirmatory hemodynamic or
radiographic features: pulmonary capillary wedge pressure
(PCWP) $15 mm Hg and cardiac index #2.2 l/min/m2
(for non-anterior MI) or pulmonary congestion on a chest
X-ray, with subsequent hemodynamic confirmation (for
anterior MI). Moreover, only patients with CS due to
predominant LV failure with ECG evidence of recent total
coronary occlusion, e.g., ST elevation, Q waves, new left
bundle branch block (LBBB) or posterior MI with anterior
ST depression, were eligible for the trial.
Enrollment in the SHOCK Trial Registry, however,
which forms the basis for the current report, required only
that CS be suspected on clinical grounds. Etiologies of CS
other than predominant LV failure (e.g., acute severe mitral
regurgitation [MR], ventricular septal rupture [VSR], iso-
lated right ventricular [RV] failure, cardiac tamponade or
rupture, prior severe valvular heart disease, excess beta or
calcium channel blockade, dilated cardiomyopathy, and CS
associated with recent hemorrhage or cardiac catheteriza-
tion laboratory complication) constituted clinical exclusion
criteria in the SHOCK Trial, and patients with such
etiologies were entered into the SHOCK Trial Registry.
Patients with VSR or acute severe MR without CS were not
registered, because the diagnosis of suspected CS was
required. Patients with any etiology of CS whose course was
outside the time windows of CS #36 h after MI and
randomization #12 h after shock diagnosis were also
included in the SHOCK Trial Registry.
Data from the 302 patients enrolled in the randomized
SHOCK Trial between April 1993 and November 1998
(11) are presented: 1) to assess the effect of revascularization
on mortality in the SHOCK Trial Registry, compared to
the SHOCK Trial, and 2) to assess the incidence of major
etiologies of shock for all screened (Registry and Trial)
patients. For the latter analysis, we included only the 232
predominant LV failure patients enrolled in the Trial as of
August 31, 1997, the time period concurrent with Registry
enrollment. Mortality rates for the major shock etiologies
are presented for: 1) all Registry patients, 2) the predomi-
nant LV failure cohort within the Registry and 3) the
Registry and concurrent Trial patients combined.
Data collection. Data were abstracted from the medical
record by the SHOCK study coordinators, who were
centrally trained to complete standardized study report
forms. Patient characteristics, MI characteristics, hemody-
namics, medication and procedure utilization, and vital
status at hospital discharge were recorded.
Definitions. Predominant LV failure was designated as the
etiology of CS when none of the other following major
shock categories was indicated as present: isolated RV
shock, mechanical cause (acute severe MR, VSR, or tam-
ponade/LV rupture), prior severe valvular heart disease,
excess beta or calcium channel blockade, or shock resulting
from a cardiac catheterization laboratory complication.
ECG locations were defined as follows (GUSTO I) (13):
V1 2 V4 Anterior; II, III, AVF Inferior;
V5 2 V6 Apical; I, AVL Lateral; V1 2 V2 Posterior.
Abbreviations and Acronyms
CK 5 creatine kinase
CS 5 cardiogenic shock
LBBB 5 left bundle branch block
LV 5 left ventricular, left ventricle
MI 5 myocardial infarction
MR 5 mitral regurgitation
PCWP 5 pulmonary capillary wedge pressure
RV 5 right ventricular, right ventricle
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?
VSR 5 ventricular septal rupture
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Reinfarction was defined as follows: 1) recurrent chest pain
or ischemic symptoms $30 min and recurrent ST-segment
elevation, new Q waves, or new LBBB; 2) total creatine
kinase (CK) at least twice the upper limit of normal and
.25% or 200 U/mL over the previous value, with an
elevated CK-MB level; or 3) a rise in CK-MB above the
upper limit of normal after it had reverted to the normal
range.
Hemodynamic data. Right heart catheterization was per-
formed in 790 Registry patients, with PCWP recorded in
739 patients and cardiac index in 562 patients. Left ven-
tricular (LV) ejection fraction was measured at any time
during the hospitalization in 468 patients, by LV angiog-
raphy (37%), gated blood pool scan (4%) or echocardiogra-
phy (59%). Hemodynamic measurements included those
recorded while the patient was receiving supportive therapy.
Statistical methods. The characteristics of patients with
predominant LV failure versus other causes of shock were
compared using the Fisher exact test for categorical vari-
ables, the Wilcoxon rank-sum test for ordinal and non-
normally distributed continuous variables, and Student
t-test for normally distributed continuous variables. Median
values are presented with 25th and 75th percentiles, and
means with standard deviation. In six patients there were
multiple causes of shock, and for the purposes of compari-
son of mortality rates these patients were categorized as
having one cause based on the following hierarchical rank-
ing: 1) predominant LV failure, 2) VSR, 3) severe MR, 4)
isolated RV failure, 5) cardiac tamponade and 6) other cause
of shock. The p values reported for the comparisons of these
groups are unadjusted for multiple comparisons. Four pa-
tients are included in the overall mortality analysis; but the
etiology of shock was unknown, and these patients are not
included in any shock subgroup. Logistic regression was
used to model mortality (dead vs. alive) of patients with
predominant LV failure by revascularization status, with
adjustment for factors associated with selection for revascu-
larization. Forty-one patients were excluded from modeling,
because the revascularization attempt occurred before shock
onset. Models, including cardiac index as a covariate, were
restricted (by definition) to patients undergoing right heart
catheterization, approximately half of all predominant LV
failure patients. All analyses were conducted using the
Statistical Analysis System (SAS Institute; Cary, North
Carolina).
Results. Eleven hundred and ninety patients were regis-
tered as of August 31, 1997, the closing date of the
SHOCK Trial Registry database. The SHOCK Trial ran-
domized 232 patients with predominant LV failure during
the concurrent period of April 1993 through August 1997
and an additional 70 patients as of the completion of Trial
enrollment on November 30, 1998. Characteristics of the
patients in the Registry are shown in Table 1. The mean age
was 68.7 6 11.8 years, and 40.3% were women. There were
high rates of history of MI, hypertension, diabetes and
smoking.
Major shock categories. The incidences of the major
categories of shock were assessed. Predominant LV failure
caused CS in 78.5% of all (Registry and Trial, n 5 1,422)
cases. Acute severe MR was diagnosed in 98 (6.9%), VSR in
55 (3.9%), isolated RV shock in 40 (2.8%), tamponade/
rupture in 20 (1.4%) and other causes (as defined in the
Methods section) in 95 (6.7%) (Fig. 1). Six patients fell into
more than one category (see the Methods section), and four
patients could not be categorized.
MI characteristics of Registry patients. Multiple-site in-
farct locations were often noted on ECG (50%). Anterior
MI was diagnosed in 55%, inferior in 46%, posterior in 19%,
lateral in 32%, apical in 11% and unknown in 10%.
Electrocardiographic evidence of ST elevation and/or Q
waves or new LBBB MI was present in 79.1%. Median time
from MI to shock was 7.0 h (25th to 75th percentile, 1.8 to
22.0). The highest creatine phosphokinase was elevated a
median of 8.4 times (25th to 75th percentile, 2.9 to 18.6)
above the upper limit of normal. Recurrent MI and recur-
rent ischemia occurred between the initial MI associated
with hospital admission and shock in 9.3% and 19.7% of
patients, respectively, and were associated with hypotension
in 86.1% and 69.5%, respectively.
Hemodynamics and pharmacologic support. The hemo-
dynamic values for all Registry patients, including those
with predominant LV failure causing CS (Table 2), were
most often recorded after support measures (IABP and/or
vasopressors) were instituted. For the 790 who underwent
right heart catheterization, the range of cardiac index and
PCWP was broad. Pharmacologic support included vaso-
pressors in 95.1% (dopamine 89.3%, norepinephrine 31.6%,
epinephrine 41.9%) and/or dobutamine in 70.1%.
Predominant LV failure. In the Registry group with
predominant LV failure (n 5 884), patients were more
likely to have had prior MI (40.1% vs. 29.5%, p 5 0.001)
Table 1. Registry Patient Characteristics
All
Patients
Predominant
LV Failure
Other
Categories
n 1,190 884 306
Age (yrs) 68.7 6 11.8 68.5 6 12.1 69.5 6 11.1
Male (%) 59.7 63.6 48.3*
White, non-
Hispanic (%)
82.0 83.6 77.4**
History of MI (%) 37.4 40.1 29.5***
History of hypertension (%) 53.1 51.7 57.2
Diabetes (%) 32.6 32.8 32.0
Smoker (%) 50.1 51.5 45.9
History of elevated lipids
(%)
41.8 40.2 46.4
History of renal
insufficiency (%)
10.9 10.7 11.6
History of PTCA (%) 6.2 6.7 4.8
History of CABG (%) 9.6 10.1 8.1
Other severe illness (%) 18.1 17.7 19.4
History of peripheral
vascular disease (%)
17.9 18.8 15.4
*p , 0.0001 vs. LV failure; **p 5 0.019 vs. LV failure; ***p 5 0.001 vs. LV failure.
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and to be white (83.6% vs. 77.4%, p 5 0.019), compared
with patients in the other shock categories (Table 1).
Women represented a smaller proportion of the Registry
patients with predominant LV failure, compared with the
other shock categories (36.4% vs. 51.7%, p , 0.0001).
Otherwise, there were no significant differences in the
patient characteristics of those with predominant LV failure
compared to those in the other shock categories. Among
LV failure patients, anterior MI location on ECG was most
common (58.8%), although 34.4% had inferior MI without
anterior involvement. Of the latter, 100 (38.3%) had a prior
MI. Therefore, 21.2% of those with predominant LV failure
had a first inferior MI with no anterior involvement. Over
half of this subgroup (53.4%) had lateral, posterior and/or
apical involvement on ECG.
Mortality. In-hospital mortality for the major shock cate-
gories is shown in Figure 1, with an overall (Registry and
concurrent Trial combined) rate of 60.1%. The rates were
significantly different among the six etiologies. Ventricular
septal rupture patients had higher mortality (87.3%) than
those with predominant LV failure (p 5 0.0002), RV shock
(p 5 0.002), MR (p 5 0.0001), as well as every other
category (p , 0.01). The mean in-hospital LV ejection
fraction of 257 Registry survivors was significantly higher
than that of 211 nonsurvivors (34.3 6 13.7% vs. 30.4 6
13.7%, p , 0.002). Within the predominant LV failure
subgroup, the mean LV ejection fraction for 196 survivors
was higher than that of 143 nonsurvivors (32.9 6 12.8 % vs.
27.4 6 11.7%, p , 0.0001). Registry patients who were
transferred (44%) to the SHOCK Trial tertiary care center
had a markedly lower mortality than direct admissions
(56%) to those centers (54% vs. 67%, p 5 0.001).
Procedure utilization and outcome for Registry patients
with predominant LV failure. Registry patients were clin-
ically selected (not randomized) to undergo different treat-
ments, which were not mutually exclusive. Thrombolytic
therapy was administered in 36%, while IABP was placed in
53%. Thrombolytic therapy alone (15%), IABP use alone
(33%), and thrombolytic therapy with IABP use (20%) were
each associated with lower mortality than no IABP or no
thrombolytic therapy use (32%) (62.9%, 52.6%, 46.5% vs.
76.5% in-hospital mortality, respectively, p , 0.005).
Left heart cardiac catheterization with coronary angiog-
raphy and revascularization performed at any time during
the hospitalization are shown in Figure 2. Also shown are
in-hospital mortality rates for patients undergoing early
percutaneous transluminal coronary angioplasty (PTCA) or
coronary artery bypass graft surgery (CABG) within 18 h of
shock diagnosis. This timing of revascularization corre-
Figure 1. The complete population of all shock patients screened, including 1,190 Registered patients and 232 Trial patients randomized concurrent with
the Registry from 4/93 – 8/97, is represented in the figure. Of the 1,116 patients with LVF, 844 were Registry and 232 were Trial. The mortality rates
for the 1,190 Registry patients and 884 LVF Registry patients are 61.4% and 60.8%, respectively. The incidence (%, below each bar) and mortality for the
major shock categories is shown. LVF 5 predominant LV failure (see Methods section), RVF 5 isolated RV shock, MR 5 acute severe mitral
regurgitation, VSR 5 ventricular septal rupture, Tamp 5 cardiac tamponade/rupture. Other causes are described in the methods section. The categorization
of cardiogenic shock was unknown in four patients who had a 75% mortality rate. Between group comparisons are based on hierarchical groups in order
from left to right. Six patients fell into more than one category (see text).
Table 2. Hemodynamic Profile of Registry Patients*
All Registry
Patients
(n 5 1,190)
Predominant
LV Failure
(n 5 884)
n Mean 6 SD N Mean 6 SD
Systolic BP (mm Hg) 1,124 87.7 6 22.3 833 88.4 6 23.0
Diastolic BP (mm Hg) 976 52.3 6 17.0 729 52.7 6 17.2
Heart rate (mm Hg) 1,121 95.7 6 26.2 832 95.2 6 25.8
PCWP (mm Hg) 739 23.4 6 8.4 534 23.7 6 8.6
Cardiac index (1/min/m2) 562 2.08 6 0.77 408 2.06 6 0.78
PA systolic (mm Hg) 482 41.2 6 12.8 341 41.1 6 12.8
PA diastolic (mm Hg) 484 23.6 6 7.8 343 23.8 6 8.0
LV ejection fraction (%) 468 32.6 6 13.8 339 30.6 6 12.6
*Measurements were most often obtained on support measures; sympathomimetic
amines and/or intra-aortic balloon counterpulsation
BP 5 Blood pressure; LV 5 Left ventricular; PA 5 Pulmonary artery; PCWP 5
Pulmonary capillary wedge pressure.
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sponds to the upper time limit for early revascularization
after shock in the SHOCK Trial. Left ventricular assist
devices were used in 0.8% (based on 856 with available
data). Performance of coronary angiography, PTCA, and
CABG were each associated with lower in-hospital mortal-
ity rates than in patients managed without these treatments
(Fig. 2). Reports on IABP and thrombolysis (14), and
angiographic findings (15), appear in this supplementary
issue of the Journal.
Registry patients undergoing PTCA and CABG at any
time during the shock hospitalization were younger (64.2 6
11.6 vs. 72.0 6 11.3 years, p , 0.0001), had a lower
incidence of prior MI (35.3% vs. 44.2%, p 5 0.009),
diabetes (28.2% vs. 36.7%, p 5 0.009), and prior CHF
(12.8% vs. 25.7%, p , 0.0001), and a higher cardiac index
(2.2 6 0.8 vs. 1.9 6 0.7 l/min/m2, p 5 0.001) and LV
ejection fraction (32.1 6 12.4 % vs. 28.5 6 12.7 %, p 5
0.005), and more often had CS diagnosis within 6 h of MI
(48.2% vs. 39.6%, p 5 0.02). The odds ratio (OR) for death,
after adjusting for selection factors, for patients undergoing
PTCA or CABG, compared with those without revascu-
larization, is shown in Table 3. The effect of revasculariza-
tion observed in the SHOCK Trial was obtained by
comparing all trial patients undergoing a revascularization
attempt at any time during hospitalization with those who
did not (without regard to group assignment). The OR for
death with revascularization in the SHOCK Trial was 0.35,
similar to the adjusted OR of 0.30 observed in the SHOCK
Trial Registry cohort. Table 4 summarizes the impact of
revascularization within 18 h of CS, compared with no or
late revascularization. In this analysis Trial patients were
grouped according to their assigned treatment strategy
because the upper time limit for early revascularization was
18 h (12). The adjusted OR for death with early revascu-
Figure 2. Patients with predominant LV failure clinically selected to undergo left heart catheterization and coronary angiography (LH cath) had a lower
mortality than those with no LH cath. Patients with no revascularization attempt had higher mortality, with the lowest mortality observed in patients
selected to undergo CABG. The CABG group includes 18 patients who underwent CABG post-PTCA; these patients are not included in the PTCA
group. The mortality rates for those undergoing early revascularization (within 18 h of shock diagnosis), at a time comparable to the randomized SHOCK
Trial, are shown. The median times to PTCA and CABG are 2.8 and 3.9 h, respectively, for those revascularized ,18 h post-shock.
*Patients with PTCA or CABG prior to shock are excluded.
Table 3. Effect of Revascularization on Mortality
Odds Ratio for Death Revascularization vs. No Revascularization
n
Odds
Ratio 95% CI Comments
Trial 302 0.35 0.22, 0.55 170 underwent a
(30-Day mortality)* revascularization attempt
vs. 132 who did not
undergo revascularization†
Registry 800 0.18 0.13, 0.25 Unadjusted
(In-hospital mortality) 800 0.22 0.16, 0.30 Adjusted for age, diabetes,
MI to CS ,6 h
389 0.30 0.19, 0.47 Adjusted for cardiac index,
age, diabetes, prior MI
*Trial in-hospital and 30-day mortality were similar. †Revascularization was performed at any time during the hospitalization
and includes all revascularized patients without regard to trial group assignment (11).
CI 5 Confidence interval.
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larization in the Registry was 0.46, again roughly similar to
the Trial OR of 0.69.
DISCUSSION
Major causes of CS. The relative incidence of the various
causes of CS has not been previously reported in a well-
defined large prospective study. The most frequent cause of
CS is predominant LV failure, most often with ECG
findings consistent with recent total coronary occlusion MI
with anterior location. Although inferior MI occurred often,
it was associated with prior MI in more than one-third of
the patients, or was associated with a mechanical cause of
shock. This supports the view that inferior MI alone
infrequently causes shock due to extensive LV dysfunction.
Mechanical causes of CS, including VSR, acute severe
MR, and tamponade—all requiring early recognition and
repair—accounted for 12% of cases. The mortality rate
when VSR was the cause of shock was significantly higher
than that associated with other categories, emphasizing the
need for rapid septal repair before CS develops (16,17). It is
worth noting that the mortality rate associated with cardiac
tamponade, which is often due to sub-acute cardiac rupture,
was relatively low (18,19). This emphasizes the potential for
improving survival with early detection.
Patient profile. The characteristics of patients who de-
velop CS in the SHOCK Trial Registry are remarkably
similar to those in many other reports of CS (5,13,20 –
22). Patients with CS are often elderly and female and
have high rates of prior MI, hypertension and diabetes.
The timing of shock after MI onset, however, appears to
be markedly shorter than previously reported (5,13,20).
Whether this discrepancy results from the prospective
nature of a registry dedicated exclusively to CS or from a
change in the pathogenesis and/or the timing of CS is
unknown.
Mortality. The overall mortality for patients with CS in
this SHOCK Trial Registry is 60%, which is lower than the
80% to 90% rate in previous reports (21,22). This may be
explained partly by the fact that 44% of the patients in the
SHOCK Trial Registry were transferred from community
hospitals. Not surprisingly, patients transferred to SHOCK
Trial tertiary care centers had significantly lower mortality
than direct admissions to the SHOCK Trial centers. This is
attributed to the survival bias associated with transfer.
Nevertheless, the mortality (67%) in the cohort with direct
admission remains lower than previous reports, perhaps
because of the increased utilization of IABP and revascu-
larization. Although the mean LV ejection fraction was
significantly lower for nonsurvivors, the 4% to 6% point
difference carries no clear clinical import with respect to
patient stratification or pathophysiologic understanding.
Outcome with thrombolysis and IABP. Patients selected
to receive thrombolysis or IABP had lower mortality rates
than those not receiving those therapies, and the combina-
tion appeared to be additive (14). Experimental evidence
suggests that the depressed rates of thrombus dissolution are
restored when IABP is used with thrombolysis in a hypo-
tensive model (23,24). Similarly, nonrandomized clinical
studies have reported lower mortality for these combined
therapies (25,26). Whether this combination is superior to
thrombolysis alone for pump failure complicating acute MI
is being tested in the randomized Thrombolysis and Coun-
terpulsation to Improve Cardiogenic Shock Survival Trial
(TACTICS) and How Effective are Revascularization Op-
tions in Cardiogenic Shock Trial (HEROICS).
PTCA and CABG. Previous studies, largely retrospective,
have demonstrated an association between the use of PTCA
or CABG and lower mortality (6–10,27–34). The outcome
of revascularization performed at the SHOCK centers very
closely replicates the pooled rates from these studies. The
mortality of LV failure patients undergoing PTCA at any
time during the hospitalization for CS complicating acute
MI is 45% for 646 patients in 22 studies (6–10,27),
compared with 46% mortality for the 290 patients in the
SHOCK Trial Registry. The 28% mortality rate for LV
failure patients undergoing CABG in our Registry is re-
markably similar to the pooled 35% mortality for 391
patients in 25 studies undergoing CABG at any time during
the hospitalization for CS (27–33). Furthermore, the out-
come with PTCA and CABG in the randomized SHOCK
Trial was similar to these outcomes in the Registry (11).
Our observation that the mortality rate associated with
Table 4. Effect of Early Revascularization on Mortality
Odds Ratio for Death Revascularization Within 18 h of Shock vs. No/Late Revascularization
n
Odds
Ratio 95% CI Comments
Trial 302 0.69 0.44, 1.08 152 randomly assigned to early
(30-Day mortality)* revascularization and 150 to
no early revascularization
Registry 753 0.37 0.27, 0.51 Unadjusted
(In-hospital mortality) 753 0.46 0.33, 0.66 Adjusted for age, diabetes,
MI to CS ,6 h
353 0.58 0.35, 0.98 Adjusted for cardiac index and
age, diabetes, prior MI
*Trial in-hospital and 30-day mortality were similar.
CI 5 Confidence interval.
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revascularization is significantly lower than that associated
with no revascularization is consistent with previous reports.
The patient characteristics of those clinically selected to
undergo revascularization are significantly different from
those not selected and explain a large part of the mortality
difference. In fact, the randomized SHOCK Trial demon-
strated only 9% absolute and 17% relative mortality reduc-
tion at 30 days (similar to the outcome at hospital discharge)
for early revascularization, compared with initial medical
stabilization. The latter group often underwent IABP sup-
port and thrombolysis, and delayed revascularization was
performed in 25% (11). The effect of early revascularization
in the large Registry is somewhat greater than in the Trial
after adjustment for differences in all characteristics except
for hemodynamics, which were available only in a subset.
After adjustment for the better hemodynamic profile of
those selected for revascularization, the effect of early
revascularization was similar in both the Trial and Registry.
It is possible that the small difference between ORs in favor
of a greater benefit of early revascularization in the Registry,
compared with the Trial, is attributable to the more fre-
quent use of IABP and thrombolysis in the initial medical
stabilization arm of the Trial than in the Registry. Overall,
the similarity of treatment effect in patients undergoing
revascularization in the Registry and Trial provides strong
support for the generalizability of the SHOCK Trial results
to patients with CS complicating acute MI. Of note, the
Trial reported increasing benefits of early revascularization
over time, with a large and significant mortality reduction at
six months consistent with 13 lives saved per 100 patients
treated (11).
In summary, the overall mortality for CS complicating
acute MI in this international registry is lower than previ-
ously reported, although CS due to VSR remains associated
with very high mortality. This lower-than-expected mortal-
ity rate is likely due to higher revascularization rates in this
Registry, consistent with similar findings in a recent popu-
lation study and randomized trial (11,35).
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